Sk Bioscience Co.,ltd.

SK bioscience Secures Funding to Advance RSV Preventive Antibody Development with RIGHT Foundation Support

SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union

SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute

SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family

SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding